Abstract：To investigate the features of metachronous urothelial transitional cell carcinoma(TCC) and its metachronous characteristics. Methods: A retrospective analysis of patients in our hospital with transitional cell carcinoma of the urinary tract during 1994-2015, and 24 cases developedcontralateralup urinary tract transitional cell cancer. Results: 4 cases are males in 24 cases and 19 casesare females, time interval to recurrenceis 1-124 months, with an average of 49.1 months. Follow-up time arranged from 1 to 116 months, average 42 months.18 casesdied, and five cases survived. Conclusions: Urothelial tumors have multifocal features and high recurrence rate which should be strengthened research in early detectionand early diagnosis.
[1]Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012,62(1):10-29. [2]Cosentino M, Palou J, Gaya JM, et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol, 2013,31(1):141-145. [3]Novara G, De Marco V, Dalpiaz O, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int, 2008,101(11):1368-1374. [4]Novara G, De Marco V, Dalpiaz O, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol, 2009,16(2):187-191. [5]Crocetti E, Arniani S, Buiatti E. Synchronous and metachronous diagnosis of multiple primary cancers. Tumori, 1998,84(1):9-13. [6]Hafner C, Knuechel R, Zanardo L, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene, 2001,20(35):4910-4915. [7]Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer, 2003,98(8):1620-1626. [8]Zhang B, Shen C, Han WK, et al. Comparison of clinicopathologic characteristics of urothelial carcinoma between patients after renal transplantation and on dialysis. Transplantation, 2014,98(5):552-556. [9]Fang D, Zhang L, Li X, et al. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. J Cancer Res Clin Oncol, 2014,140(3):477-485. [10]Gadzinski AJ, Roberts WW, Faerber GJ, et al. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol, 2010,183(6):2148-2153. [11]Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol, 2008,53(4):720-731. [12]Cutress ML, Stewart GD, Wells-Cole S, et al. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int, 2012,110(11):1608-1617. [13]田野,侯海军,郭宇文,等.肾移植患者单侧上尿路上皮肿瘤术后对侧尿路预防性切除的必要性.北京大学学报(医学版), 2013,45(4):558-561. [14]Hou HJ, Xiao J, Tian Y. Contralateral nephroureterectomy for renal transplant recipients with unilateral upper urinary tract transitional cell carcinoma: a report of 12 cases. Transplant Proc, 2013,45(6):2203-2206. [15]Holmng S, Johansson SL. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol, 2006,175(1):69-73.
